Troels Jordansen | Chief Executive Officer
Glycostem Therapeutics

Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics

Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over ?150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 13:30

Panel discussion: Rise of allogeneic cells and allo-approaches to oncology & non-oncology

·The cell types·Impact of gene editing·Cellular Persistence·Cellular phenotypes·Expansion In vivo·Possibility of retreatment·Lymphodepletion·Administration of the cells/ Amount of the cells/Local and systemic administration

Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 16:30

Panel: VC financing during COVID

·Money is flowing freely·What happens once these funds are paid out?·What drove them to high valuations? (without having met in person, over zoom)
last published: 10/May/21 08:45 GMT

back to speakers